Current users of NSAIDs were subsequently
divided into “single” and “multiple” users (the latter
included those patients with two or more NSAIDs recorded in
the current use window), and according to the dose (Appendix 1
in supplementary material), duration of consecutive prescriptions,
action duration (12 h half-life or
slow-release preparations), and main indication (osteoarthritis,
rheumatoid arthritis, others)